Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 7 | 2025 | 286 | 2.670 |
Why?
|
| RNA, Long Noncoding | 6 | 2025 | 240 | 2.050 |
Why?
|
| MicroRNAs | 8 | 2025 | 918 | 1.190 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2025 | 19 | 1.130 |
Why?
|
| RNA, Untranslated | 3 | 2025 | 112 | 1.110 |
Why?
|
| Gene Regulatory Networks | 4 | 2018 | 385 | 1.050 |
Why?
|
| Fatty Acids | 3 | 2019 | 356 | 1.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 2057 | 1.000 |
Why?
|
| Dried Blood Spot Testing | 3 | 2023 | 26 | 0.970 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2025 | 145 | 0.850 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 347 | 0.780 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2019 | 67 | 0.780 |
Why?
|
| Bevacizumab | 2 | 2025 | 80 | 0.750 |
Why?
|
| Wound Healing | 2 | 2025 | 477 | 0.740 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 1028 | 0.740 |
Why?
|
| Transcriptome | 3 | 2025 | 1125 | 0.740 |
Why?
|
| Metabolomics | 5 | 2024 | 480 | 0.670 |
Why?
|
| Cytokines | 1 | 2025 | 1358 | 0.600 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 136 | 0.560 |
Why?
|
| Chromatography, Liquid | 5 | 2025 | 239 | 0.550 |
Why?
|
| Neoplasms | 4 | 2025 | 2954 | 0.540 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 351 | 0.510 |
Why?
|
| Sequence Analysis, RNA | 3 | 2023 | 408 | 0.500 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 945 | 0.490 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 125 | 0.490 |
Why?
|
| RNA, Messenger | 3 | 2025 | 2674 | 0.470 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 921 | 0.460 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 806 | 0.450 |
Why?
|
| Computational Biology | 4 | 2014 | 874 | 0.440 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 102 | 0.440 |
Why?
|
| RNA Interference | 2 | 2014 | 514 | 0.410 |
Why?
|
| Humans | 30 | 2025 | 132061 | 0.310 |
Why?
|
| Gene Expression Profiling | 5 | 2023 | 1882 | 0.270 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 3014 | 0.270 |
Why?
|
| Radiation Tolerance | 2 | 2025 | 64 | 0.270 |
Why?
|
| Drug Monitoring | 2 | 2025 | 174 | 0.250 |
Why?
|
| Systems Biology | 1 | 2025 | 62 | 0.230 |
Why?
|
| Trastuzumab | 1 | 2025 | 143 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3681 | 0.220 |
Why?
|
| Ribonuclease III | 1 | 2025 | 99 | 0.220 |
Why?
|
| Digoxin | 1 | 2024 | 39 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 2648 | 0.220 |
Why?
|
| Teicoplanin | 1 | 2024 | 5 | 0.220 |
Why?
|
| Febrile Neutropenia | 1 | 2024 | 15 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 146 | 0.210 |
Why?
|
| Urinary Catheterization | 1 | 2024 | 86 | 0.210 |
Why?
|
| Plasma | 1 | 2023 | 102 | 0.200 |
Why?
|
| Catheter-Related Infections | 1 | 2024 | 136 | 0.190 |
Why?
|
| Digestion | 1 | 2021 | 43 | 0.180 |
Why?
|
| Hematocrit | 1 | 2021 | 112 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 295 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 553 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 299 | 0.170 |
Why?
|
| Carnitine | 1 | 2021 | 69 | 0.170 |
Why?
|
| Proteins | 4 | 2023 | 1036 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 317 | 0.160 |
Why?
|
| Solid Phase Microextraction | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2019 | 12 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 4757 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2025 | 1960 | 0.160 |
Why?
|
| Oncogenes | 2 | 2018 | 175 | 0.150 |
Why?
|
| RNA | 1 | 2023 | 551 | 0.150 |
Why?
|
| Genomics | 2 | 2025 | 1646 | 0.150 |
Why?
|
| Sequence Analysis, Protein | 3 | 2008 | 48 | 0.150 |
Why?
|
| Vaccination | 1 | 2024 | 1018 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 729 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 220 | 0.150 |
Why?
|
| Subcellular Fractions | 2 | 2008 | 90 | 0.140 |
Why?
|
| Databases, Genetic | 2 | 2018 | 501 | 0.140 |
Why?
|
| Immobilized Proteins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Calibration | 1 | 2018 | 99 | 0.140 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 930 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 46 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2017 | 78 | 0.140 |
Why?
|
| Magnets | 1 | 2017 | 23 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 333 | 0.130 |
Why?
|
| Mice | 6 | 2025 | 18507 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4688 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 434 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 209 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 198 | 0.130 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 215 | 0.130 |
Why?
|
| Cell Line | 2 | 2021 | 2719 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 256 | 0.130 |
Why?
|
| Voriconazole | 1 | 2014 | 34 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 753 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 166 | 0.110 |
Why?
|
| Genome, Human | 1 | 2021 | 1330 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 604 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2019 | 550 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2014 | 430 | 0.100 |
Why?
|
| Animals | 6 | 2025 | 34882 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 123 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2508 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1032 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2558 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 767 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2014 | 312 | 0.090 |
Why?
|
| Binding Sites | 1 | 2014 | 1256 | 0.090 |
Why?
|
| Proteomics | 2 | 2006 | 596 | 0.090 |
Why?
|
| Protein Structure, Secondary | 3 | 2008 | 246 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 438 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1538 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 1728 | 0.090 |
Why?
|
| Cell Survival | 2 | 2025 | 865 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2025 | 241 | 0.080 |
Why?
|
| Female | 9 | 2024 | 70712 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 2 | 2007 | 73 | 0.080 |
Why?
|
| Male | 6 | 2025 | 64922 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 65 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2011 | 363 | 0.070 |
Why?
|
| Sequence Alignment | 1 | 2007 | 615 | 0.060 |
Why?
|
| Biotransformation | 1 | 2024 | 56 | 0.060 |
Why?
|
| Microbial Interactions | 1 | 2024 | 16 | 0.060 |
Why?
|
| Biomarkers | 1 | 2014 | 3406 | 0.060 |
Why?
|
| Inflammation | 2 | 2024 | 1517 | 0.050 |
Why?
|
| Pancreas | 1 | 2025 | 222 | 0.050 |
Why?
|
| Mutation | 1 | 2018 | 6229 | 0.050 |
Why?
|
| Methanol | 1 | 2023 | 16 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 9957 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2023 | 49 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1610 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 21406 | 0.050 |
Why?
|
| Relative Biological Effectiveness | 1 | 2021 | 8 | 0.040 |
Why?
|
| Acetylcarnitine | 1 | 2021 | 3 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 687 | 0.040 |
Why?
|
| Oxides | 1 | 2021 | 15 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 346 | 0.040 |
Why?
|
| Methylamines | 1 | 2021 | 21 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 28964 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 394 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 98 | 0.040 |
Why?
|
| Choline | 1 | 2021 | 51 | 0.040 |
Why?
|
| Carbon | 1 | 2021 | 94 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2020 | 57 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1672 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 83 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 764 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 118 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 235 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 163 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 561 | 0.040 |
Why?
|
| Gene Drive Technology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Adipocytes | 1 | 2020 | 178 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 240 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 217 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 2669 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 219 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 96 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 94 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 433 | 0.040 |
Why?
|
| RNA Precursors | 1 | 2018 | 66 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 182 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 3770 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 149 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 664 | 0.030 |
Why?
|
| Protein Domains | 1 | 2018 | 260 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 167 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 412 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2020 | 504 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11658 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 31568 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 321 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2018 | 764 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 1798 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1573 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 689 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3736 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1116 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 803 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 728 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 2899 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6567 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3380 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 1122 | 0.020 |
Why?
|
| Software | 2 | 2006 | 732 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 254 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 2493 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 2391 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 5009 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 13028 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1436 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 125 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3418 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3350 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4703 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 651 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17419 | 0.020 |
Why?
|
| Bacteriorhodopsins | 1 | 2006 | 3 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 588 | 0.020 |
Why?
|
| Protein Sorting Signals | 1 | 2006 | 41 | 0.020 |
Why?
|
| Solvents | 1 | 2006 | 44 | 0.020 |
Why?
|
| Protein Folding | 1 | 2006 | 223 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 827 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 470 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 392 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 492 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 7102 | 0.010 |
Why?
|
| Child | 1 | 2023 | 25789 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 697 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 847 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2320 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 20562 | 0.010 |
Why?
|